by dyadic | Jul 28, 2026 | Press Releases
Delivery of the Bundibugyo viral antigens to Fondazione Biotecnopolo di Siena (“FBS”) and Scripps Research demonstrates C1’s potential to accelerate vaccine and monoclonal antibody development, expand platform adoption, and create future commercial...
by dyadic | Jul 24, 2026 | Press Releases
JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life...
by dyadic | Jul 16, 2026 | Press Releases
New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platformJUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic...
by dyadic | Jul 7, 2026 | Press Releases
C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant FundingJUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a...
by dyadic | Jun 29, 2026 | Press Releases
Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein SolutionsJUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) — Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a...
by dyadic | Jun 15, 2026 | Press Releases
Company’s C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial marketsJUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) —...
